MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.39
+0.12
+1.65%
Opening 14:06 09/24 EDT
OPEN
7.16
PREV CLOSE
7.27
HIGH
7.63
LOW
7.16
VOLUME
408.93K
TURNOVER
--
52 WEEK HIGH
25.50
52 WEEK LOW
4.880
MARKET CAP
292.29M
P/E (TTM)
-10.6792
1D
5D
1M
3M
1Y
5Y
James Levine Is The Chief Financial Officer of Cardiff Oncology, Inc. (NASDAQ:CRDF) And Just Spent US$194k On Shares
Potential Cardiff Oncology, Inc. ( NASDAQ:CRDF ) shareholders may wish to note that the Chief Financial Officer, James...
Simply Wall St. · 09/15 10:37
Cardiff Oncology (CRDF) Stock Jumps 7%: Will It Continue to Soar?
Zacks.com · 09/14 11:31
Cardiff Oncology Inc (CRDF) CFO James E. Levine Bought $194,100 of Shares
GuruFocus News · 09/13 17:15
Insider Buy: Cardiff Oncology
MT Newswires · 09/13 09:22
Hot Stocks: BIIB Alzheimer’s woes; CRDF, CNTA clinical trial data; PRQR partnership deal; RKLB jumps on earnings
Biotech and drug development news dominated Thursday's midday action. This included Biogen (NASDAQ:BIIB), which dropped to a multi-month low after its CEO warned of slower-than-expected adoption of its controversial Alzheimer’s
Seekingalpha · 09/09 17:11
LULU, FRO and PMCB among pre market gainers
Soligenix (NASDAQ:SNGX) +26% FDA Grants soligenix orphan drug designation for the treatment of T-cell lymphoma Eloxx Pharmaceuticals (NASDAQ:ELOX) +22% announces fast track designation for ELX-02 for the treatment of cystic fibrosis patients
Seekingalpha · 09/09 12:21
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
21 Stocks Moving in Thursday's Pre-Market Session
Gainers
Benzinga · 09/09 10:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRDF. Analyze the recent business situations of Cardiff Oncology Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRDF stock price target is 25.33 with a high estimate of 26.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 106
Institutional Holdings: 27.04M
% Owned: 68.36%
Shares Outstanding: 39.55M
TypeInstitutionsShares
Increased
23
6.31M
New
32
1.78M
Decreased
24
3.81M
Sold Out
15
1.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.00%
Pharmaceuticals & Medical Research
-1.03%
Key Executives
Chairman/Director
Rodney Markin
Chief Executive Officer/Director
Mark Erlander
Chief Financial Officer
James Levine
Other
Katherine Ruffner
Director
Thomas Adams
Independent Director
James Armitage
Independent Director
Paul Billings
Independent Director
John Brancaccio
Independent Director
Gary Jacob
Independent Director
Mani Mohindru
Independent Director
Gary Pace
Independent Director
Renee Tannenbaum
Independent Director
Lale White
No Data
  • All
  • Financials
  • Insiders
More
About CRDF
Cardiff Oncology Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatment for cancer patients. Its drug candidate includes onvansertib , which is a novel polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. The Company's clinical trail includes TROV-052 , a Phase I b/2 open-label clinical trial of onvansertib in combination with standard-of-care low-dose cytarabine (LDAC) , TROV-053 a Phase II open-label clinical trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone and TROV-054 a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and Avastin (bevacizumab). Its clinical development programs include tumor genomics and biomarker technology to enable assessment of patient response to treatment.

Webull offers kinds of Cardiff Oncology Inc stock information, including NASDAQ:CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.